A new analysis of data from a large international registry finds that use of beta-blockers in patients with and without a history of coronary artery disease does not reduce cardiovascular events.

(AUDIO) According to the Centers for Disease Control, more than one-third of US adults are obese. The CDC also estimates that as many as 1.4 million Americans suffer from inflammatory bowel disorder. So is there a link?

(AUDIO) What is the natural history of systemic corticosteroid therapy in ulcerative colitis? Insights here from Dr Nabeel Khan, Assistant Professor of Medicine in Gastroenterology & Hepatology at Tulane Medical Center-author of a new study on this topic.

At an "exciting" time in HIV treatment, the Affordable Care Act offers the prospect of immediate treatment for newly diagnosed HIV. In this podcast, the author of a new report on the topic discusses how the Act will affect your patients' care.

In 2000, MI was defined as any necrosis in the setting of myocardial ischemia. The 2007 update to this definition recognized that different conditions can lead to myocardial necrosis and 5 types of myocardial infarctions were defined.

It is high season for this potentially deadly viral infection, cases of which have been reported in every state. Will you be prepared? Guidance here from an expert.

For two HIV-positive patients, treatments with bone marrow transplants for cancer have achieved eradication of the virus from their blood cells. Learn in this podcast what this portends for the future.

Dr Farris Timimi, Assistant Professor of Medicine at the Mayo Clinic and Medical Director of the Mayo Clinic Center for Social Media, discusses the potential of social media to change the landscape of clinical practice.

Omega-3 fatty acids used to treat patients with dysglycemia in the ORIGIN trial failed to reduce cardiovascular death or ischemic events. Follow-up was 6 years.

In this podcast, the chair of the International Antiviral Society USA tells why it now advises immediate antiretroviral treatment for everyone diagnosed with HIV infection.

Achieving sustained reductions of hyperlipidemia and blood pressure in a patient with diabetes is not impossible, but it's a challenge. A new study comparing two health systems shows which factors increase the odds of success.

The popular media recently took a look at the connection between systemic inflammation and the many human diseases it’s responsible for. A lengthy article in the Wall Street Journal focused on the role of daily diet in the development and modulation of inflammation and noted the clinical use of biomarker C-reactive protein to measure inflammation levels. Harvard cardiologist Christopher Cannon offered tips on eating to beat inflammation and shed pounds at the same time from his new book titled The Complete Idiot’s Guide to the Anti-Inflammation Diet. Alarming health news paired with a new book on diet can create a perfect storm of questions from you patients.

Ticagrelor is the newest P2Y12 inhibitor approved to treat patients with unstable angina or non-ST elevation myocardial infarction. AHA/ACC guideline update.

Far too many HIV-positive patients get that bad news after their very first HIV test, nationwide data show. Hear a CDC expert tell why primary care doctors are key to improving HIV testing rates and saving lives.

Some say chlorthalidone is superior to hydrochlorothiazide and should be used as first-line therapy in hypertension. A compelling case can be made for resurrecting this venerable drug.

Novel anticoagulants (dabigatran, rivaroxaban, apixaban) are gaining wide acceptance over warfarin, for their simplicity of use and proven efficacy.

Statin medications were associated with significant tiredness and exertional fatigue in men and women without cardiovascular disease or diabetes.

Azithromycin has been linked to sudden cardiac death in patients with cardiovascular disease that require an antibiotic.

A genetic analysis questions the benefits of raising HDL-C levels to reduce the risk of MI and of the value of HDL-C as a surrogate marker of risk.

Use of aspirin in primary prevention of cardiovascular disease must be based on individual risk-benefit analysis and is not appropriate for patients at low risk.